Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2813 - Survival after resection of colorectal cancer with synchronous metastases – a Danish population based historical cohort study


08 Oct 2016


Poster Display


Anders Boysen


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


A.K. Boysen1, A.G. Ording2, H.T. Sørensen2, D.K. Farkas2, K. Spindler1

Author affiliations

  • 1 Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 2 Clinical Epidemiology, Aarhus University Hospital, 8200 Aarhus N - Aarhus C/DK


Abstract 2813


Conflicting data exist on the optimal treatment for resectable synchronous metastatic disease in liver and/or lungs in patients with colorectal cancer (CRC). We examined the long term survival of a large national cohort of patients resected for CRC and timing of treatment for synchronous metastasectomies.


From 2000-2013 we included all patients from the Danish Cancer Registry and the Danish National Patient Registry recorded with CRC surgery for adenocarcinoma We also obtained data from the Danish National Patient Registry for patients operated for liver and/or lung metastases synchronously (


A total of 35.993 patients had surgery for colon (n = 24.206) or rectal cancer (n = 11.787) (46,4% females (n = 16.711) and 53,6% males (n = 19.282)). 2.625 patients (7,3%) were surgically treated for metastatic disease with liver and/or lung surgery. 117 patients (0,3%) had liver surgery prior to CRC surgery while 1.458 patients (4,1%) underwent liver surgery following resection of the primary tumour. 106 patients (0,3%) were operated for lung metastases before and 944 patients (2,6%) after the CRC surgery. The 1 and 5 year overall survival for the entire cohort of patients were 84,1% (83,8%-84,5%) and 56,7% (56,1%-57,2%) respectively. For the subset of patients undergoing synchronous metastasectomy the 1 and 5 year survival were 88,0% (85,3%-90,2%) and 41,4% (36,9%-45,9%).


We found a 5 year survival of 41,4 % in patients treated for synchronous metastatic disease with liver and/or lung surgery

Clinical trial identification

Legal entity responsible for the study

Aarhus University Hospital


Aarhus University Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings